Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug ...

Cell and gene therapy: Dr. Jeff Hersh examines 25 years of technological advances In general, earlier stage cancers have ...

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or ...

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...

A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...

To aid researchers in ADC development, BioIVT provides Ki67 staining procedures with pre-stained blocks and custom screens.

Collecting and storing comprehensive data on human biospecimens is essential for generating high-quality, reproducible ...

Monoclonal antibodies—treatments developed by cloning a cell that makes an antibody—could help provide an answer to the ...